AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® (tivozanib), has opted into the …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA® (tivozanib) for …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) share are climbing nearly 9% in pre-market trading Monday, after the drug maker announced that the European Commission (EC) has …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported financial results for the second quarter ended June 30, 2017, and provided a business update.
New insights emerge in the biotech sector as Cara Therapeutics Inc (NASDAQ:CARA) released mixed results from a phase 2b trial of the company’s pain medication, …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock tumbled nearly 9% in early trading Tuesday, after the drug maker announced that it has secured $14 million in …
AVEO Pharmaceuticals Shares Skyrocket on Positive CHMP Opinion It’s a very rewarding trading day for investors in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) with shares up over …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) and Biodesix announced the presentation of results from two investigator-sponsored Phase 1 studies of ficlatuzumab at the 2017 American Society …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) investors are having a rough morning, after the drug maker announced that it has priced an underwritten public offering of …
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported financial results for the third quarter ended September 30, 2016.
